Eyenovia, Inc. (NASDAQ: EYEN) is a biopharmaceutical company founded with the mission to revolutionize ophthalmic therapeutics through innovative delivery systems. The company focuses on improving the usability and administration of eye medications using its proprietary Optejet® device, the only FDA-approved ophthalmic spray alternative to traditional eye drops. Eyenovia's pipeline includes advanced therapeutics aimed at addressing the limitations of conventional eye drop bottles, ensuring precise dosing and enhancing patient experience.
Notable figures affiliated with Eyenovia include its leadership team and key investors who have supported its vision of transforming eye care. The company's significant achievements include the FDA approval of the Optejet® device, positioning it as a leader in ophthalmic drug delivery technology. Eyenovia's impact is evident in its commitment to improving patient outcomes and setting new standards in the ophthalmic industry.
